A simple method for assessing intestinal inflammation in Crohn's disease
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationGut. 2000, 47(4):506-13
AbstractBACKGROUND AND AIMS: Assessing the presence and degree of intestinal inflammation objectively, simply, and reliably is a significant problem in gastroenterology. We assessed faecal excretion of calprotectin, a stable neutrophil specific marker, as an index of intestinal inflammation and its potential use as a screening test to discriminate between patients with Crohn's disease and those with irritable bowel syndrome. METHODS: The validity of faecal calprotectin as a marker of intestinal inflammation was assessed in 22 patients with Crohn's disease (35 studies) by comparing faecal excretions and concentrations using four day faecal excretion of (111)indium white cells. A cross sectional study assessed the sensitivity of faecal calprotectin concentration for the detection of established Crohn's disease (n=116). A prospective study assessed the value of faecal calprotectin in discriminating between patients with Crohn's disease and irritable bowel syndrome in 220 patients referred to a gastroenterology clinic. RESULTS: Four day faecal excretion of (111)indium (median 8.7%; 95% confidence interval (CI) 7-17%; normal <1.0%) correlated significantly (p<0.0001) with daily (median ranged from 39 to 47 mg; normal <3 mg; r=0.76-0.82) and four day faecal calprotectin excretion (median 101 mg; 95% CI 45-168 mg; normal <11 mg; r=0.80) and single stool calprotectin concentrations (median 118 mg/l; 95% CI 36-175 mg/l; normal <10 mg/l; r=0.70) in patients with Crohn's disease. The cross sectional study showed a sensitivity of 96% for calprotectin in discriminating between normal subjects (2 mg/l; 95% CI 2-3 mg/l) and those with Crohn's disease (91 mg/l; 95% CI 59-105 mg/l). With a cut off point of 30 mg/l faecal calprotectin has 100% sensitivity and 97% specificity in discriminating between active Crohn's disease and irritable bowel syndrome. CONCLUSION: The calprotectin method may be a useful adjuvant for discriminating between patients with Crohn's disease and irritable bowel syndrome.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease?
- Authors: Crama-Bohbouth G, Pena AS, Biemond I, Verspaget HW, Blok D, Arndt JW, Weterman IT, Pauwels EK, Lamers CB
- Issue date: 1989 Sep
- Faecal calprotectin in the assessment of Crohn's disease activity.
- Authors: Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, Liddell C, Stanley AJ, Morris AJ, Mackenzie JF
- Issue date: 2005 Jun
- Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology.
- Authors: Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB
- Issue date: 2004 Sep 15
- Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
- Authors: Summerton CB, Longlands MG, Wiener K, Shreeve DR
- Issue date: 2002 Aug
- Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
- Authors: Oyaert M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H
- Issue date: 2014 Mar